Paroxetine updated on 07-01-2025

Neural Tube Defects

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S7470
R22258		 Anderson, 2020 Any neural tube defect 1st trimester case control unexposed (general population or NOS) Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 1.40 [0.70;2.80] -/-   0/- - -
ref
S7350
R21500		 Wemakor, 2015 Neural tube defects 1st trimester case control unexposed (general population or NOS) Adjustment: No Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 0.23 [0.01;3.85] C 0/27   1,322/18,378 1,322 27
ref
S6160
R16183		 Louik, 2007 Neural-tube defects 1st trimester case control unexposed (general population or NOS) Adjustment: Yes Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) 3.30 [1.10;10.40] 4/34   316/6,146 320 34
ref
Total 3 studies 1.61 [0.63;4.10] 1,642 61
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Anderson, 2020Anderson, 2020 1.40[0.70; 2.80]--54%ROB confusion: seriousROB selection: criticalROB classification: criticalROB missing: lowROB mesure: unclearROB reporting: moderate Wemakor, 2015Wemakor, 2015 0.23[0.01; 3.85]1,3222710%ROB confusion: criticalROB selection: criticalROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Louik, 2007Louik, 2007 3.30[1.10; 10.40]3203436%ROB confusion: moderateROB selection: criticalROB classification: criticalROB missing: lowROB mesure: criticalROB reporting: moderate Total (3 studies) I2 = 44% 1.61[0.63; 4.10]1,642610.210.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0 case control studiescase control studies 1.61[0.63; 4.10]1,6426144%NAAnderson, 2020 Wemakor, 2015 Louik, 2007 3 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.61[0.63; 4.10]1,6426144%NAAnderson, 2020 Wemakor, 2015 Louik, 2007 3 Tags Adjustment   - No  - No 0.23[0.01; 3.85]1,32227 -NAWemakor, 2015 1   - Yes  - Yes 1.91[0.85; 4.28]3203438%NAAnderson, 2020 Louik, 2007 2 Monotherapy   - substance alone among all Antidep ( ...  - substance alone among all Antidep (SSRI, SNRI, ...) 0.98[0.24; 3.97]1,3222732%NAAnderson, 2020 Wemakor, 2015 2   - substance alone among the specific ...  - substance alone among the specific class of antidep (SSRI, SNRI, ...) 3.30[1.07; 10.15]32034 -NALouik, 2007 1 All studiesAll studies 1.61[0.63; 4.10]1,6426144%NAAnderson, 2020 Wemakor, 2015 Louik, 2007 30.110.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.61[0.63; 4.10]1,6426144%NAAnderson, 2020 Wemakor, 2015 Louik, 2007 30.510.01.0